|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2017
|
|
gptkbp:ATCCode
|
L01XC28
|
|
gptkbp:brand
|
gptkb:Imfinzi
|
|
gptkbp:CASNumber
|
1428935-60-7
|
|
gptkbp:chemicalFormula
|
C6400H9844N1732O1992S46
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contraindication
|
hypersensitivity to durvalumab
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugClass
|
immunotherapy
|
|
gptkbp:halfLife
|
~17 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
durvalumab
|
|
gptkbp:indication
|
gptkb:locally_advanced_or_metastatic_urothelial_carcinoma
unresectable stage III non-small cell lung cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:IgG1_kappa
|
|
gptkbp:mechanismOfAction
|
PD-L1 inhibitor
|
|
gptkbp:molecularWeight
|
~148 kDa
|
|
gptkbp:monotherapyOrCombination
|
combination drug
monotherapy
|
|
gptkbp:origin
|
human monoclonal antibody
|
|
gptkbp:patent
|
gptkb:AstraZeneca
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:prescriptionRequired
|
available from FDA and EMA
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
cough
rash
pneumonitis
immune-mediated adverse reactions
|
|
gptkbp:target
|
gptkb:programmed_death-ligand_1_(PD-L1)
|
|
gptkbp:UNII
|
6K08GVY5Q1
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:cancer
bladder cancer
|
|
gptkbp:bfsParent
|
gptkb:Imfinzi
|
|
gptkbp:bfsLayer
|
6
|